Celcuity Inc., a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. The company is developing CELx tests to diagnose two new sub-types of HER2-negative breast cancer. It is also developing CELx tests to diagnose 14 new potential cancer sub-types in breast, lung, colon, ovarian, kidney, bladder, and hematological cancers. The company was founded in 2012 and is headquartered in Minneapolis, Minnesota.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone763-392-0767
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/13/2019 (Estimated)
OptionableNot Optionable
Celcuity (NASDAQ:CELC) Frequently Asked Questions
What is Celcuity's stock symbol?
Celcuity trades on the NASDAQ under the ticker symbol "CELC."
How were Celcuity's earnings last quarter?
Celcuity Inc (NASDAQ:CELC) posted its quarterly earnings data on Thursday, August, 9th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.17) by $0.02. View Celcuity's Earnings History.
When is Celcuity's next earnings date?
What price target have analysts set for CELC?
2 analysts have issued 12-month price targets for Celcuity's stock. Their forecasts range from $35.00 to $36.00. On average, they anticipate Celcuity's share price to reach $35.50 in the next year. This suggests a possible upside of 74.5% from the stock's current price. View Analyst Price Targets for Celcuity.
What is the consensus analysts' recommendation for Celcuity?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celcuity in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Celcuity.
What are Wall Street analysts saying about Celcuity stock?
Here are some recent quotes from research analysts about Celcuity stock:
- 1. According to Zacks Investment Research, "Celcuity Inc. is a cellular analysis company. It engaged in discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The company's proprietary CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular activity driving a patient's cancer and the targeted therapy. Celcuity Inc. is based in Minneapolis, United States. " (2/28/2019)
- 2. HC Wainwright analysts commented, "Our price target is derived from a market value of the firm at $369M, which includes a discounted cash flow based asset value for CELx tests, with a 15% discount rate and 0.5% terminal growth rate. Probabilities of success assigned are 45% and 10% for breast cancer and colon cancer, respectively. Risks include, but are not limited to: (1) failure of CELx tests in clinical trials; (2) failure of CELx tests to secure CDx regulatory approval; and (3) failure of CELx tests to achieve commercial success due to market size, penetration rate, and/or competition." (12/10/2018)
Has Celcuity been receiving favorable news coverage?
Media headlines about CELC stock have been trending somewhat positive on Friday, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Celcuity earned a coverage optimism score of 0.6 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near future.
Who are some of Celcuity's key competitors?
Some companies that are related to Celcuity include RadNet (RDNT), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), Fulgent Genetics (FLGT), PotNetwork (POTN), Psychemedics (PMD), First Choice Healthcare Solutions (FCHS), OpGen (OPGN), CBA Florida (CBAI), Cancer Genetics (CGIX), Aeon Global Health (AGHC), Biocept (BIOC), Avant Diagnostics (AVDX) and Foundation Medicine (FMI).
What other stocks do shareholders of Celcuity own?
Who are Celcuity's key executives?
Celcuity's management team includes the folowing people:
- Mr. Brian F. Sullivan, Co-Founder, Chairman, CEO & CFO (Age 57)
- Dr. Lance G. Laing, Co-Founder, Chief Science Officer, VP, Sec. & Director (Age 57)
- Ms. Vicky Hahne, Chief Financial Officer (Age 53)
- Ms. Laura Beggrow RN, Chief Commercial Officer (Age 56)
- Mr. Larry Fitzgerald, VP of Strategic Partnerships & Managed Markets (Age 48)
When did Celcuity IPO?
(CELC) raised $18 million in an IPO on Wednesday, September 20th 2017. The company issued 2,000,000 shares at $8.00-$10.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO.
Who are Celcuity's major shareholders?
Celcuity's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.84%), Gagnon Securities LLC (1.72%), ARS Investment Partners LLC (0.70%), Northern Trust Corp (0.61%), Geode Capital Management LLC (0.34%) and Geode Capital Management LLC (0.34%). View Institutional Ownership Trends for Celcuity.
Which institutional investors are selling Celcuity stock?
CELC stock was sold by a variety of institutional investors in the last quarter, including Gagnon Securities LLC, BlackRock Inc., Accredited Investors Inc. and SNS Financial Group LLC. View Insider Buying and Selling for Celcuity.
Which institutional investors are buying Celcuity stock?
CELC stock was bought by a variety of institutional investors in the last quarter, including ARS Investment Partners LLC, JNBA Financial Advisors, Kessler Investment Group LLC, Geode Capital Management LLC, Geode Capital Management LLC, Northern Trust Corp and Strs Ohio. View Insider Buying and Selling for Celcuity.
How do I buy shares of Celcuity?
Shares of CELC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Celcuity's stock price today?
One share of CELC stock can currently be purchased for approximately $20.34.
How big of a company is Celcuity?
Celcuity has a market capitalization of $207.67 million. The company earns $-7,480,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis.
What is Celcuity's official website?
How can I contact Celcuity?
Celcuity's mailing address is 16305 36TH AVENUE N SUITE 100, MINNEAPOLIS MN, 55446. The company can be reached via phone at 763-392-0767.
MarketBeat Community Rating for Celcuity (NASDAQ CELC)
MarketBeat's community ratings are surveys of what our community members think about Celcuity and other stocks. Vote "Outperform" if you believe CELC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CELC will underperform the S&P 500 over the long term. You may vote once every thirty days.
